Efficacy of ranibizumab combined with photocoagulation for diabetic retinopathy: A meta-analysis study

Ranibizumab addition may benefit to improve the efficacy in patients with diabetic retinopathy than only photocoagulation, and this meta-analysis aims to explore the impact of ranibizumab addition on efficacy for diabetic retinopathy. METHODS: PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials assessing the effect of ranibizumab addition on patients with diabetic retinopathy for this meta-analysis. RESULTS: Six randomized controlled trials were finally included in the meta-analysis. Overall, compared with control intervention for diabetic retinopathy, ranibizumab addition showed significantly increased number of neovascularization area reduction (OR = 4.20; 95% CI = 1.47–12.02; P = .007) and reduced fluorescein leakage (MD = −2.53; 95% CI = −3.31 to −1.75; P < .00001), but showed no obvious impact on neovascularization area (MD = −1.80; 95% CI = −3.68 to 0.08; P = .06), photocoagulation retreatment (OR = 1.03; 95% CI = 0.47–2.27; P = .94) or adverse events (OR = 1.45; 95% CI = 0.49–4.29; P = .50). CONCLUSIONS: Ranibizumab combined with photocoagulation is effective to improve efficacy for diabetic retinopathy.